Story perspectives

Eli Lilly Cuts Zepbound Prices Following Novo Nordisk's Lead

12/1/2025

Summary

Story summary

On December 1, 2025, Eli Lilly announced a price reduction for Zepbound, with cash prices for single-dose vials starting at $299 per month.
The move follows Novo Nordisk's price reductions for Ozempic and Wegovy, and both companies reached agreements with U.S. President Donald Trump's administration to improve affordability.
The new prices are available through LillyDirect, while Novo Nordisk's discounts apply to retail partners to increase access.

History

Historical Context

The American Patients First initiative, launched by the Trump administration in 2018, aimed to reduce prescription drug prices, which are among the highest globally. This initiative spurred negotiations with pharmaceutical companies like Eli Lilly and Novo Nordisk, resulting in price cuts of up to 30%. In 2023, the U.S. spent over $600 billion on medications, highlighting ongoing affordability challenges for patients.

1 of 2

Story summary

On December 1, 2025, Eli Lilly announced a price reduction for Zepbound, with cash prices for single-dose vials starting at $299 per month.
The move follows Novo Nordisk's price reductions for Ozempic and Wegovy, and both companies reached agreements with U.S. President Donald Trump's administration to improve affordability.
The new prices are available through LillyDirect, while Novo Nordisk's discounts apply to retail partners to increase access.

1 / 2